New Interleukin-23 Antagonists’ Use in Crohn’s Disease

Crohn’s disease (CD) is a chronic inflammatory condition of the digestive tract, driven by an imbalance in immune system regulation, where proinflammatory interleukin-23 (IL-23) plays an essential role. Selective new IL-23 inhibitors, including risankizumab, guselkumab, and mirikizumab, block the IL...

Full description

Bibliographic Details

Published in:	Pharmaceuticals
Main Authors:	Laura Biskup, Jan Semeradt, Jagoda Rogowska, Wiktoria Chort, Łukasz Durko, Ewa Małecka-Wojciesko
Format:	Article
Language:	English
Published:	MDPI AG 2025-03-01
Subjects:	Crohn’s disease IL-23 inhibitors risankizumab guselkumab mirikizumab inflammatory bowel disease
Online Access:	https://www.mdpi.com/1424-8247/18/4/447